Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting

pharmafile | March 23, 2023 | News story | Business Services  

Tokyo, Japan and Cambridge, UK, 23 March 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, announces the election of Ms. Eiko Tomita to the Board of Directors as an Independent External Director, and the promotion of Ms. Candelle Chong to Executive Vice President and Chief of Staff at the Company’s 33rd Annual Shareholders’ Meeting and a subsequent Board of Directors meeting, held today in Tokyo.


Shinichi Tamura, Chairman of Sosei Heptares, said: “I am thrilled to welcome Eiko to the Board of Directors at Sosei Heptares. She is a highly experienced pharmaceutical executive, and her deep knowledge of drug development, regulatory affairs and product commercialization, both internationally and in Japan, will be a significant addition as the Company drives its core strategy towards becoming one of Japan’s biopharmaceutical champions.” 


Chris Cargill, President & CEO of Sosei Heptares, added: “I would like to congratulate Candelle on her well-deserved promotion. This newly created role is key to the successful management and growth of Sosei Heptares and will benefit from Candelle’s proven track record in strategy implementation and operations across multiple areas such as business development, corporate finance transactions, communications, investor relations and human resources.”




Ms. Eiko Tomita

Eiko has over 35 years’ experience in the pharmaceutical industry, both internationally and in Japan, having held roles across R&D, business strategy and commercialization at several global biopharmaceutical companies. Eiko currently serves as Vice President, Global Regulatory Affairs at Bristol Myers Squibb where she oversees regulatory affairs in over 40 countries. Prior to joining Bristol Myers Squibb in 2007, Eiko held roles at Pfizer, AstraZeneca, Monsanto and Eisai.


Eiko is a qualified pharmacist and holds an MBA from the University of Wales, Cardiff.

Ms. Candelle Chong

Candelle joined Sosei Heptares in April 2018 as Vice President Corporate Strategy and was promoted to Executive Vice President and Chief of Staff in March 2023. Candelle has also held interim positions as Head of Human Resources and Head of Site Operations and has managed group strategic projects, corporate finance transactions, internal and external communications, and investor relations.


Prior to joining Sosei Heptares, Candelle spent over five years in healthcare investment banking at J.P. Morgan in Sydney, Australia and in London, UK. She holds a Bachelor of Laws (Hons.) and a Bachelor of Commerce (Finance) from the University of New South Wales, Australia.


Further details of the Board of Directors and Executive Officers


Board of Directors (effective 23 March 2023)

Chairman of the Board                                                            Shinichi Tamura (reappointed)

Representative Executive Officer                                                         Chris Cargill (reappointed)

Independent External Director                                              Tomohiro Tohyama (reappointed)

Independent External Director                                              Kuniaki Kaga (reappointed)

Independent External Director                                              David Roblin (reappointed)

Independent External Director                                              Noriaki Nagai (reappointed)

Independent External Director                                              Rolf Soderstrom (reappointed)

Independent External Director                                              Miwa Seki (reappointed)

Independent External Director                                              Eiko Tomita (appointed)                     


Executive Officers (effective 23 March 2023)

President & Chief Executive Officer                                                    Chris Cargill

EVP, President of Heptares Therapeutics, Head of UK R&D            Matt Barnes

EVP, Chief Financial Officer                                                                   Hironoshin Nomura

EVP, Chief Accounting Officer                                                              Kieran Johnson

EVP, Chief Compliance Officer                                                              Kazuhiko Yoshizumi

EVP, Chief of Staff                                                                                   Candelle Chong


Related Content

No items found

Latest content